Weighing Benefits and Risks of Cell Therapy in Multiple Myeloma: Suzanne Lentzsch, MD


The professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, New York-Presbyterian Hospital, discussed utility of cellular therapies in multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Suzanne Lentzsch, MD, professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, College of Physicians and Surgeons of Columbia University, Columbia University Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, about the utility of cellular therapies in multiple myeloma.

Lentzsch discussed how established or emerging cellular therapies may be able to be adapted for patients based on age to provide the longest remissions while minimizing toxicity risk, although definitive data are not yet available. For example, CAR T-cell therapy will likely be the first choice for a younger patient because there may be a higher likelihood of the modality leading to prolonged remission or cure in this patient population, Lentzsch adds.

However, older patients are at an increased risk of developing CAR T-cell therapy–related toxicities, such as neurotoxicity, Lentzsch says. As such, other emerging cellular therapies, such as antibody-drug conjugates and bispecific T-cell engagers, could provide durable responses without significant toxicity in older patients with multiple myeloma, Lentzsch explains. Additional data are needed to determine whether these novel cellular therapies are also able to be used in younger patients, Lentzsch concludes.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.